Results with Rituxan
Rituxan, in combination with glucocorticoids, is an FDA-approved therapy for adults with Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA). Talk with your doctor to see if Rituxan may be right for you.
In a clinical trial, Rituxan, in combination with glucocorticoids, was proven to put GPA and MPA into complete remission
The Rituximab in ANCA-Associated Vasculitis (RAVE) trial was conducted by the National Institute of Allergy and Infectious Diseases and the Immune Tolerance Network with support from Genentech and Biogen Idec. The goal of the trial was to see if Rituxan worked as well as cyclophosphamide in bringing on complete remission* in adults with GPA and MPA.
The RAVE trial showed that 64% of people taking Rituxan achieved complete remission by 6 months compared with 53% of patients taking cyclophosphamide (control group). The study also showed that there were no major differences between the overall side effects of Rituxan and cyclophosphamide.
Common side effects of Rituxan include infusion reactions, chills, infections, body aches, tiredness, low white blood cells, aching joints during or within hours of receiving an infusion, and more frequent upper respiratory tract infection. Other more serious side effects may include severe infusion reactions, severe skin and mouth reactions, hepatitis B virus (HBV) reactivation, progressive multifocal leukoencephalopathy (PML), tumor lysis syndrome (TLS), and serious infections.
- In this trial, "complete remission" was defined as no disease activity and no need for steroid therapy.